BostonGene’s cloud-based software platform, bioinformatics capabilities, analytical tools, and advanced next-generation sequencing (NGS) support doctors in finding the most effective strategy for personalized treatment options for their patients.
BostonGene’s state-of-the-art molecular testing laboratory performs next-generation sequencing technologies, including whole-exome and whole-transcriptome sequencing, multiplex immunofluorescence imaging, flow cytometry, and proteomics. Comprehensive reports on the unique molecular portraits of tumors are generated using sophisticated analytics and bioinformatics.
Samples are processed at the BostonGene laboratory. The laboratory is CLIA and CAP-accredited, and holds a permit from New York State in Oncology: Molecular and Cellular Tumor Markers:
Certification Numbers
CLIA: 22D2182613
CAP: 8832984
NY: 9637
The BostonGene platform integrates data obtained by genomics, transcriptomics, and microenvironment analysis to enable personalized decisions and the delivery of optimized therapeutics.
BostonGene personalizes AI for medical experts to create a vast and continually updated database of biomarkers, therapies, clinical trials, and therapeutic guidelines.
